About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study Evaluating MYO-029 in Adult Muscular Dystrophy

NCT00104078·9 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Wyeth is now a wholly owned subsidiary of Pfizer

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Written informed consent.
Confirmed clinical and molecular diagnosis of Becker Muscular Dystrophy (BMD), Facioscapulohumeral Muscular Dystrophy (FSHD), or Limb-Girdle Muscular Dystrophy (LGMD)
Independently ambulatory

You may not be if

Patients with certain clinical conditions
Patients using steroids or other medications with the potential to affect muscle function
History of sensitivity to monoclonal antibodies or protein pharmaceuticals
Pregnant or lactating women.

The record

StatusCompleted

PhasePhase 1–2

Taking part108

StartedFeb 2005

UpdatedDec 28, 2007

Conditions

Becker Muscular Dystrophy Facioscapulohumeral Muscular Dystrophy Limb-Girdle Muscular Dystrophy

Where9

Washington D.C., District of Columbia, United States
Kansas City, Kansas, United States
Baltimore, Maryland, United States

Clareo Health | Study Evaluating MYO-029 in Adult Muscular Dystrophy